The lack of change in GLUT-1 expression in response to BRAF/MEK inhibition in YUMM1.7 xenografts suggest that this reduction in not due to a decrease in glucose uptake by the cells, but potentially to a decrease in the glycolytic activity of the tumor cells. Here, SLC2A1 is linked to neoplasm.